Interline Therapeutics Raises $92M in Funding
The round was led by Foresite Capital and ARCH Venture Partners.
The company intends to use the funds to expand the research platform and advance six preclinical therapeutic programs.
Co-founded by CEO Zachary Sweeney, Interline Therapeutics is a Foresite Labs incubated company that focuses on systematically elucidating protein communities to define molecular mechanisms of disease.
The company uses genomics, proteomics, structural biology and computational chemistry to systematically map and modulate protein communities. Interline Therapeutics is leveraging recent advancements in these technologies, as well as collaborations with academic groups, to develop a precision medicine platform focused on three essential areas: